Cefepime-taniborbactam and CERTAIN-1: Can we treat carbapenem-resistant infections?

Wagenlehner and colleagues 1 Wagenlehner F.M. Gasink L.B. McGovern P.C. Moeck G. McLeroth P. Dorr M. Dane A. Henkel T. CERTAIN-1 Study TeamCefepime-Taniborbactam in Complicated Urinary Tract Infection. N. Engl. J. Med. 2024; 390: 611-622https://doi.org/10.1056/NEJMoa2304748 Crossref Scopus (2) Google Scholar demonstrated non-inferiority and superiority with respect to a primary endpoint of composite success (microbiological plus clinical) of cefepime/taniborbactam vs. meropenem in treating complicated urinary tract infections and acute pyelonephritis caused by carbapenem-susceptible gram-negative bacteria in adults. A major area of interest in real-world application of cefepime/taniborbactam is its potential role in treating carbapenem-resistant infections, which deserves further investigation. Wagenlehner and colleagues 1 Wagenlehner F.M. Gasink L.B. McGovern P.C. Moeck G. McLeroth P. Dorr M. Dane A. Henkel T. CERTAIN-1 Study TeamCefepime-Taniborbactam in Complicated Urinary Tract Infection. N. Engl. J. Med. 2024; 390: 611-622https://doi.org/10.1056/NEJMoa2304748 Crossref Scopus (2) Google Scholar demonstrated non-inferiority and superiority with respect to a primary endpoint of composite success (microbiological plus clinical) of cefepime/taniborbactam vs. meropenem in treating complicated urinary tract infections and acute pyelonephritis caused by carbapenem-susceptible gram-negative bacteria in adults. A major area of interest in real-world application of cefepime/taniborbactam is its potential role in treating carbapenem-resistant infections, which deserves further investigation.